Reata Pharmaceuticals (RETA) News Today

Braun Stacey Associates Inc. cut its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 47.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 164,775 shares of the company's stock after selling 146,235 shares during the pe

Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) has been given a consensus rating of "Hold" by the thirteen ratings firms that are covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation and four have issued a buy recommendatio

First Light Asset Management LLC decreased its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 23.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,586,928 shares of the

HighTower Advisors LLC trimmed its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 6.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,978 shares of the company's stock after s

Credit Suisse AG boosted its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 6.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 41,476 shares of the company's stock after purchasing an additional 2,334 share

Swiss National Bank reduced its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 10.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,200 shares of the company's stock afte

Pictet Asset Management SA bought a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,204 shares of the company's stock, valued at approximately $291,000. Several

Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) was the recipient of some unusual options trading activity on Friday. Investors acquired 5,018 put options on the company. This is an increase of 180% compared to the typical volume of 1,794 put options.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) has been given an average recommendation of "Hold" by the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation and four have ass

US Bancorp DE lifted its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 1,280.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,646 shares of the company's stock after purchasing an additional 8,947 shares d

StockNews.com began coverage on shares of Reata Pharmaceuticals in a research note on Wednesday. They issued a "sell" rating for the company.

Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 23.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,497 shares of the company's stock after

Cantor Fitzgerald reissued a "neutral" rating and set a $172.00 price objective on shares of Reata Pharmaceuticals in a report on Tuesday.

Biondo Investment Advisors LLC purchased a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,550 shares of the company's stock, valued at approximately $323,000. A number of other

StockNews.com initiated coverage on Reata Pharmaceuticals in a research report on Monday. They set a "sell" rating for the company.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) - Research analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Reata Pharmaceuticals in a research note issued on Wednesday, August 2nd. Zacks Research analyst S. Ganoria now anticipates that the company will post ea

Integrated Wealth Concepts LLC bought a new position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,294 shares of the company's stock, valued at approxima

Citigroup downgraded Reata Pharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Tuesday.

SVB Securities cut Reata Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Friday.

Raymond James Financial Services Advisors Inc. bought a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,

DekaBank Deutsche Girozentrale reduced its stake in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 24.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,000 share

Moody Aldrich Partners LLC bought a new position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 49,529 shares of the company's stock, valued at approximately $

Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight hav